To explore a pharmacological approach for inhibiting Bub1 in lipedema ADSCs, we next employed the small molecule 2OH-BNPP1, which specifically inhibits the Serine/Threonine kinase activity of Bub1 [46]. The gene discussed is MARK2; the disease is Lipedema.